



## **Alternative Reporting Standard: Disclosure Guidelines for the Pink<sup>®</sup> Market**

Federal and state securities laws require issuers to provide *current information* to the public markets. With a view to facilitating compliance with these laws, OTC Markets Group has created these Disclosure Guidelines (“Guidelines”)<sup>1</sup> that set forth the disclosure obligations that make up the “Alternative Reporting Standard” for Pink companies. Companies on the Pink Market that do not make disclosure directly to the SEC (via EDGAR), a banking regulator, or a non-U.S. regulatory authority may provide disclosure under our “Alternative Reporting Standard.” We use information provided by companies under these Guidelines to designate the appropriate tier in the Pink Market: Current Information or Limited Information.<sup>2</sup>

### **Pink Current Information Tier**

To qualify for the Current Information Tier:

1. **Subscribe to the OTC Disclosure & News Service:** To submit an application, visit [Gateway](#) to sign in or create a new account. Allow OTC Markets Group 2-4 weeks to process your application and provide authorized user credentials to OTCIQ.

2. **Publish Initial Disclosure:** Upload the following documents through OTCIQ:

- Annual Report for the most recently completed fiscal year.
- All Quarterly Reports for the Current Fiscal Year.

*Annual or Quarterly Reports are composed of:*

- **Disclosure Statements:** Disclosure information pursuant to these Guidelines for the applicable period. Available as a fillable form beginning on page 4 of these Guidelines.
- **Financial Statements:** Qualifying Financial Statements in accordance with the Financial Statement Requirements specified in Item 9 of these Guidelines.

*Qualifying Financial Statements include:*

- Audit Letter, if audited
- Balance Sheet
- Statement of Income
- Statement of Cash Flows
- Statement of Retained Earnings (Statement of Changes in Stockholders’ Equity)
- Notes to Financial Statements

3. **Publish the annual Management Certification:** Companies must certify basic company information initially and annually within forty five (45) days of a company’s annual report due date.

4. **Verify Profile:** Verify the Company Profile through OTCIQ. This includes the complete list of current officers, directors, and service providers; outstanding shares; a business description; contact information; and the names of all company

---

<sup>1</sup> These Guidelines have been designed to encompass the “current information” requirements under state and federal securities laws, such as Rules 10b-5 and 15c2-11 of the Securities Exchange Act of 1934 (“Exchange Act”) as well as Rule 144 of the Securities Act of 1933 (“Securities Act”), and state Blue Sky laws. However, these Guidelines have not been reviewed by the U.S. Securities and Exchange Commission or any state securities regulator. These Guidelines do not constitute legal advice, and OTC Markets Group makes no assurance that compliance with our disclosure requirements will satisfy any legal requirements. These Guidelines may be amended from time to time, in the sole and absolute discretion of OTC Markets Group, with or without notice.

<sup>2</sup> OTC Markets Group may require companies with securities designated as “Caveat Emptor” or other compliance flags to make additional disclosures to qualify for the Pink Current Information tier.

insiders and beneficial owners of 10% or more of the outstanding units or shares of any class of any equity security of the issuer.

5. **OTC Markets Group Processing of Reports:** Allow OTC Markets Group to process the posted documents (typically three to five business days) and provide any comments. Companies will only be evaluated for Current Information once all required documentation has been submitted.
6. **Ongoing Requirements:** To qualify for Current Information on an ongoing basis, companies must:
  - Publish reports through OTCIQ on the following schedule:
    - Quarterly Report within **45 days** of the quarter end
    - Annual Report within **90 days** of the fiscal year end
  - Complete an annual Management Certification within **45 days** of the annual report due date.
  - Maintain a Verified Profile. At least once every six months, review and verify the Company Profile through OTCIQ.
  - Maintain Transfer Agent Verified share data. If your transfer agent participates in the [Transfer Agent Verified Shares Program](#), then your securities must have current share data verified by the transfer agent.
  - Maintain an Active standing in the Company's State of Incorporation.

### **Pink Limited Information Tier**

Companies that do not meet the requirements of the Pink Current Information tier set forth above may still qualify for the Pink Limited Information Tier by meeting the following minimum disclosure requirements.

1. **Annual Financial Statements:** Publish one set of Qualifying Annual Financial Statements which cover the past 2 completed fiscal years, provided the most recently completed fiscal year is within the past 16 months.
2. **Verified Profile:** The Company must verify the Company Profile through OTCIQ, including, but not limited to, a complete list of officers, directors, and service providers; outstanding shares; a business description; contact information; and the name of all company insiders. "Company Insiders" shall include the beneficial owner of 10% or more of the outstanding units or shares of any class of any equity security of the issuer.
3. **Ongoing Requirements:** To qualify for Limited Information on an ongoing basis, companies must:
  - Publish reports on the following schedule:
    - Annual Financial Statements as outlined in Item 9 within 120 days of the fiscal year end. Should a change in FYE occur, no more than 16 months may elapse from the fiscal year end of the prior Annual Financial Statement.
  - Review and Verify the Company's profile information through OTCIQ at least once every 12 months.
  - Maintain Transfer Agent Verified share data. If your transfer agent participates in the [Transfer Agent Verified Shares Program](#), then your securities must have current share data verified by the transfer agent.

### **Current Reporting of Material Corporate Events**

In addition to the disclosure requirements above, all companies on the Pink market are expected to promptly release to the public any news or information regarding corporate events that may be material to the issuer and its securities (including adverse information). Persons with knowledge of such events are considered to be in possession of material nonpublic information and may not buy or sell the issuer's securities until or unless such information is made public. If not included in the issuer's previous public disclosure documents, or if the material events occurs after the publication of such disclosure documents, the issuer shall publicly disclose such events by disseminating a news release **within four (4) business days**

following their occurrence and posting such news release through an Integrated Newswire or the OTC Disclosure & News Service.<sup>3</sup>

Material corporate events may include:

- Changes to the company's shell status. Please refer to our [FAQ on Shell Companies](#)
- Changes in control of issuer
- Departure of directors or principal officers; election of directors; appointment of principal officers
- Entry into or termination of a material definitive agreement or material agreement not made in the ordinary course of business
- Completion of an acquisition or disposition of assets, including but not limited to merger transactions
- Creation of a direct financial obligation or an obligation under an off-balance sheet arrangement of an issuer
- Triggering events that accelerate or increase a direct or contingent financial obligation including any default or acceleration of an obligation or an obligation under an off-balance sheet arrangement
- Costs associated with exit or disposal activities including material write-offs and restructuring; Material impairments
- Unregistered sales of equity securities
- Material modification to rights of security holders
- Changes in issuer's certifying accountant
- Non-reliance on previously issued financial statements or a related audit report or completed interim review
- Change in a company's fiscal year; Amendments to articles of incorporation or bylaws that were not previously disclosed in a proxy statement or other such disclosure statement.
- Amendments to the issuer's code of ethics, or waiver of a provision of the code of ethics
- Any changes to litigation the issuer may be involved in, or any new litigation surrounding the issuer
- Officer, director, or insider transactions in the issuer's securities
- Disclosure of investor relations, marketing, brand awareness, and stock promotion activities which might reasonably be expected to materially affect the market for its securities or otherwise deemed material by the issuer
- A company's bankruptcy or receivership
- Termination or reduction of a business relationship with a customer that constitutes a specified amount of the company's revenues
- Any material limitation, restriction, or prohibition, including the beginning and end of lock-out periods, regarding the company's employee benefits, retirement and stock ownership plan
- Earnings releases
- Other materially different information regarding key financial or operation trends from that set forth in periodic reports
- Other events the issuer determines to be material

---

<sup>3</sup> "Integrated Newswire" shall mean a newswire service that is integrated with the OTC Disclosure & News Service and is included on OTC Markets Group's list of Integrated Newswires, as published on <https://www.otcmarkets.com/corporate-services/ir-tools-services>

## CYIOS Corporation

258 SouthMilitary Trail  
Deerfield Beach, FL 33442

---

617-504-3635  
[www.cyioscorporation.com](http://www.cyioscorporation.com)  
[info@choicewellnessbrands.com](mailto:info@choicewellnessbrands.com)

# Annual Report

For the year ending December 31, 2025 (the "Reporting Period")

### Outstanding Shares

The number of shares outstanding of our Common Stock was:

337,593,993 as of 12/31/2025 (Current Reporting Period Date or More Recent Date)

337,593,993 as of 12/31/2025 (Most Recent Completed Fiscal Year End)

### Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes:  No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes:  No:

### Change in Control

Indicate by check mark whether a Change in Control<sup>4</sup> of the company has occurred during this reporting period:

Yes:  No:

#### **1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

CYIOS Corp.

---

<sup>4</sup> "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Formerly=China Printing, Inc. until 11-05  
Formerly=WorldTeq Group International, Inc.  
until 4-05 Formerly=A1 Internet.com, Inc. until  
12-01 Formerly=Halo Holdings of Nevada, Inc.  
until 5-99

Current State and Date of Incorporation or Registration: Nevada, 10/13/1997  
Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:  
N/A

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On August 2024, the company acquired 100% of the controlling interest in Noir Medical Supplies, LLC, a medical supply wholesaler.

Address of the issuer's principal executive office:

258 South Military Trail  
Deerfield Beach, FL  
33442

Address of the issuer's principal place of business:

*Check if principal executive office and principal place of business are the same address:*

\_\_\_\_\_

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No:  Yes:  If Yes, provide additional details below:

\_\_\_\_\_

## **2) Security Information**

### **Transfer Agent**

Name: Equiniti (formerly Corporate Stock Transfer)  
Phone: 651-306-4341  
Email: valeen.nowicki@equiniti.com  
Address: 1110 Centre Point Curve Suite 101 Mendota Heights, MN. 55120

**Publicly Quoted or Traded Securities:**

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	<u>CYIO</u>	
Exact title and class of securities outstanding:	<u>Common Stock</u>	
CUSIP:	<u>23128N108</u>	
Par or stated value:	<u>\$0.001</u>	
Total shares authorized:	<u>585,000,000</u>	as of date: <u>12/31/2025</u>
Total shares outstanding:	<u>337,593,993</u>	as of date: <u>12/31/2025</u>
Total number of shareholders of record:	<u>144</u>	as of date: <u>12/31/2025</u>

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

**Other classes of authorized or outstanding equity securities that do not have a trading symbol:**

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of securities outstanding:	<u>Preferred Series A</u>	
CUSIP:	<u>N/A</u>	
Par or stated value:	<u>\$.001</u>	
Total shares authorized:	<u>10,000,000</u>	as of date: <u>12/31/2025</u>
Total shares outstanding:	<u>0</u>	as of date: <u>12/31/2025</u>
Total number of shareholders of record:	<u>0</u>	as of date: <u>12/31/2025</u>

Exact title and class of securities outstanding:	<u>Preferred Series B</u>	
CUSIP:	<u>N/A</u>	
Par or stated value:	<u>\$.001</u>	
Total shares authorized:	<u>10,000</u>	as of date: <u>12/31/2025</u>
Total shares outstanding:	<u>10,000</u>	as of date: <u>12/31/2025</u>
Total number of shareholders of record:	<u>1</u>	as of date: <u>12/31/2025</u>

Exact title and class of securities outstanding:	<u>Preferred Series C</u>	
CUSIP:	<u>N/A</u>	
Par or stated value:	<u>\$.001</u>	
Total shares authorized:	<u>15,000</u>	as of date: <u>12/31/2025</u>
Total shares outstanding:	<u>15,000</u>	as of date: <u>12/31/2025</u>
Total number of shareholders of record:	<u>1</u>	as of date: <u>12/31/2025</u>

Exact title and class of securities outstanding:	<u>Preferred Series D</u>	
CUSIP:	<u>N/A</u>	
Par or stated value:	<u>\$.001</u>	
Total shares authorized:	<u>40,000</u>	as of date: <u>12/31/2025</u>
Total shares outstanding:	<u>21,850</u>	as of date: <u>12/31/2025</u>
Total number of shareholders of record:	<u>1</u>	as of date: <u>12/31/2025</u>

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

**Security Description:**

*The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:*

**1. For common equity, describe any dividend, voting and preemption rights.**

There are no defined dividend or preemption rights associated with the common equity. Each share of common stock is entitled to one vote on all shareholder matters.

**2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

Series A preferred stock. The Series A preferred stock carries a voting right of 20 votes per share and each share is convertible to 20 shares of common stock. There are no dividend, liquidation rights, redemption or sinking fund provisions.

Series B preferred stock. Each holder of outstanding shares of Series B Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock equal to 0.1% of the total number of shares of Common Stock outstanding on the record date for such vote. There are no conversion, dividend, or liquidation rights, redemption or sinking fund provisions.

Series C preferred stock. Each share of Series C Preferred Stock is convertible into a number of common shares equal to .001% of the number of common shares issued and outstanding on the date of conversion. There are no dividend, voting or liquidation rights, redemption or sinking fund provisions.

Series D preferred stock. Each share of Series D Preferred Stock is convertible into a number of common shares equal to .001% of the number of common shares issued and outstanding on the date of conversion. There are no dividend, voting or liquidation rights, redemption or sinking fund provisions.

**3. Describe any other material rights of common or preferred stockholders.**

NA

**4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.**

NA

### 3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

#### A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No:  Yes:  (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End:			*Right-click the rows below and select "Insert" to add rows as needed.						
Opening Balance									
Date <u>12/31/2023</u> Common: 240,363,756 Preferred: 55,250									
Date of transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
02/21/24	New	16,000,000	Common	\$0.001 cost per share	Yes	J-RICKS LLC Sarah Leslie	Debt Conversion	Unrestricted	4(a)(1)
7/1/24	New	16,000,000	Common	\$0.001 cost per share	Yes	J-RICKS LLC Sarah Leslie	Debt Conversion	Unrestricted	4(a)(1)
10/10/24	New	8,000,000	Common	\$0.001 cost per share	Yes	J-RICKS LLC Sarah Leslie	Debt Conversion	Unrestricted	4(a)(1)
01/2/2025	Cancel and return to Treasury	(3,500,000)	Common	\$.022	No	David Lewis	=	=	=
01/2/2025	Cancel and return to Treasury	(3,500,000)	Common	\$.022	No	John O'Shea	=	=	=
01/02/2025	New	1,250	Series D Preferred	Na	Na	David Lewis	Cancellation of 3.5M common shares	Restricted	4(a)(2)
01/02/2025	New	1,250	Series D Preferred	Na	na	John O'Shea	Cancellation of 3.5M common shares	Restricted	4(a)(2)



						Issued Upon Conversion <sup>5</sup>		
<u>01/10/2016</u>	<u>225,000</u>	<u>23,562</u>	<u>01/17/17</u>	<u>\$.001 per share</u>	214,250,000	23,562,000	<u>J-Ricks LLC</u> <u>Christopher</u> <u>Balmford</u>	<u>Loan</u>
<u>1/2/2020</u>	<u>71,839</u>	<u>94,380</u>	<u>Demand</u>	<u>25% discount to market price at time of conversion</u>	0	15,535,802	<u>OFBP</u> <u>Proprietary</u> <u>Limited</u> <u>John O'Shea</u>	<u>Loan</u>
<u>1/2/2020</u>	<u>6,264</u>	<u>8,948</u>	<u>Demand</u>	<u>N/A</u>	0	N/A	<u>OFBP</u> <u>Proprietary</u> <u>Limited</u> <u>John O'Shea</u>	<u>Loan</u>
<u>6/15/20</u>	<u>20,000</u>	<u>26,059</u>	<u>6/15/21</u>	<u>Fifty Percent (50%) of the lowest Trading Price (defined below) during the twenty (20) Trading Day period ending on the latest complete Trading Day prior to the Conversion Date.</u>	0	7,139,452	<u>GPL Ventures LLC</u> <u>Alex Dillion</u>	<u>Loan</u>
<u>10/14/20</u>	<u>\$20,000</u>	<u>27,346</u>	<u>10/14/21</u>	<u>80% of the average of the three lowest intraday trading prices during the ten (10) Trading Day period ending on the latest complete Trading Day prior to the Conversion Date.</u>	0	4,410,645	<u>GPL Ventures LLC</u> <u>Alex Dillion</u>	<u>Loan</u>
<u>3/20/22</u>	<u>\$250,000</u>	<u>\$250,000</u>	<u>3/20/22</u>	<u>Convertible at \$.025 per share</u>	0	10,000,000	<u>BB Winks LLC</u> <u>Craig Fischer</u>	<u>Loan</u>
<u>2/10/21</u>	<u>255,000</u>	<u>\$280,628</u>	<u>02/10/22</u>	<u>Convertible at \$.25 per share</u>	0	1,122,512	<u>EAGLE</u> <u>EQUITIES, LLC</u> <u>Yakov Borenstein</u>	<u>Loan</u>
<u>6/1/21</u>	<u>240,000</u>	<u>\$288,677</u>	<u>6/1/22</u>	<u>Convertible at 12.5 cents per share</u>	0	2,309,416	<u>Adar Bays, LLC.</u> <u>Aryeh Goldstein</u>	<u>Loan</u>
<u>5/4/21</u>	<u>130,000</u>	<u>\$184,935</u>	<u>5/4/22</u>	<u>Convertible at 12.5 cents per share</u>	0	1,479,480	<u>EAGLE</u> <u>EQUITIES, LLC</u> <u>Yakov Borenstein</u>	<u>Loan</u>

<sup>5</sup> The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

<u>12/20/21</u>	<u>\$175,000</u>	<u>\$57,883</u>	<u>12/20/22</u>	<u>Convertible at \$0.005 per share</u>	0	11,576,600	<u>Lance Quartieri</u>	<u>Loan</u>
<u>6/15/22</u>	<u>\$30,000</u>	<u>\$5,000</u>	<u>On Demand</u>	<u>N/A</u>	0	N/A	<u>DBL Group Bruce Lewis</u>	<u>Loan</u>
<u>7/13/22</u>	<u>\$9,800</u>	<u>\$11,000</u>	<u>On Demand</u>	<u>N/A</u>	0	N/A	<u>DBL Group Bruce Lewis</u>	<u>Loan</u>
<u>7/11/22</u>	<u>\$87,000</u>	<u>\$87,000</u>	<u>9/15/22</u>	<u>N/A</u>	0	N/A	<u>Lance Quartieri</u>	<u>Loan</u>
<u>11/20/2023</u>	<u>\$384,899</u>	<u>\$384,899</u>	<u>11/20/2024</u>	<u>Lower of 50% of closing bid or \$0.0015</u>	0	33,970,147	<u>J-Ricks LLC Sarah Leslie</u>	<u>Loan</u>
<u>7/29/24</u>	<u>\$25,000</u>	<u>\$25,000</u>	<u>7/28/2025</u>	<u>85% of any future public offering share price</u>	0	3,086,419	<u>Ralph Amato</u>	<u>Loan</u>
<u>02/10/25</u>	<u>\$25,000</u>	<u>\$25,000</u>	<u>02/09/25</u>	<u>Lower of 65% of VWAP or \$0.00025</u>	0	5,128,000	<u>Kettama Ltd Juan Campbell</u>	<u>Loan</u>
<u>02/10/25</u>	<u>\$25,000</u>	<u>\$25,000</u>	<u>02/09/25</u>	<u>Lower of 65% of VWAP or \$0.00025</u>	0	5,128,000	<u>Itmusthavebeenthe salmon, Ltd Jarred Kennedy</u>	<u>Loan</u>
<u>02/10/25</u>	<u>\$25,000</u>	<u>\$25,000</u>	<u>02/09/25</u>	<u>Lower of 65% of VWAP or \$0.00025</u>	0	5,128,000	<u>Fintan Bradley</u>	<u>Loan</u>
<u>05/30/25</u>	<u>\$47,500</u>	<u>\$47,500</u>	<u>11/30/25</u>	<u>Lower of 80% of VWAP or \$0.00025</u>	0	7,916,667	<u>Pinnacle Consulting Services Robert Hymers III</u>	<u>Loan</u>

**Total Outstanding Balance:** \$1,981,190

**Total Shares:** 214,250,000 191,153,390

Any additional material details, including footnotes to the table are below:

#### 4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on [www.OTCMarkets.com](http://www.OTCMarkets.com).

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

CYIOS Corporation (the Company) is incorporated in the State of Nevada. The Company focuses on the resale of medical devices through its wholly-owned subsidiary Noir Medical Supplies, LLC. In August 2024, the company acquired 100% of the controlling interest in Noir Medical Supplies, LLC, a medical supply wholesaler. All other operations of the Company were discontinued as of September 30, 2025

B. List any subsidiaries, parent company, or affiliated companies.

Noir Medical Supplies, LLC, a Florida company, wholly owned subsidiary (as of August 10, 2024)

C. Describe the issuers' principal products or services.

Noir Medical Supplies, LLC is a medical supply wholesaler.

## 5) Issuer's Facilities

*The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.*

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Company leases space for \$500 per month on a month-to-month basis.

## 6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

*The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.*

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, 5% Control person)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
John O'Shea	CEO/Chairman of the Board	Melbourne, Australia	10,000	Series B Preferred	100%
			15,000	Series C Preferred	100%
			21,850	Series D Preferred	100%

Confirm that the information in this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, log in to [www.OTCIQ.com](http://www.OTCIQ.com) to update your company profile.

## 7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

No

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

No

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

No

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

No

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

No

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

No

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

CYIOS Corp. v Carnahan, CASE NO. CACE-21-007984, Circuit Court of the 17<sup>th</sup> Judicial District in and For Broward County, Florida. On April 20, 2021 the Company filed a lawsuit against Timothy W. Carnahan, the former CEO of the Company. The Complaint contains six causes of action including breach of fiduciary duty, Gross Negligence, Unjust enrichment, Disgorgement pursuant to Section 304 of the Sarbanes Oxley Act of 2002, Declaratory Relief, and a Temporary Restraining Order. The Company alleges that Mr. Carnahan acted outside the scope of his authority in issuing to himself 5,000,000 shares of common stock as a performance bonus. The Company believes that the shares should be returned to the Company and canceled.

## 8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, update your company profile.

### Securities Counsel

Name: Jonathan Leinwand, Esq.  
Firm: Jonathan D. Leinwand, P.A.  
Address 1: 18305 Biscayne Blvd., Suite 200  
Address 2: Aventura, FL 33160  
Phone: 954-903-7856  
Email: jonathan@jdlpa.com

### Accountant or Auditor

Name: Zhanna Kelly  
Firm: Zhanna Kelly, CPA, PC  
Address 1: 23-23 Steinway St, Long Island City, NY 11101  
Address 2:  
Phone: 201.230.5498  
Email: Zhanna.baranets@gmail.com

### Investor Relations

Name: N/A  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

*All other means of Investor Communication:*

Twitter: @cyioscorp  
Discord: N/A  
LinkedIn: n/a  
Facebook: N/A

### Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: N/A  
Firm: N/A  
Address 1: N/A  
Address 2: N/A  
Phone: N/A  
Email: N/A

## **9) Disclosure & Financial Information**

A. This Disclosure Statement was prepared by (name of individual):

Name: John O'Shea  
Title: CEO  
Relationship to Issuer: CEO

B. The following financial statements were prepared in accordance with:

- IFRS  
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: **Zhanna Kelly**  
Title: **Accountant**  
Relationship to Issuer: **Service Provider**

Describe the qualifications of the person or persons who prepared the financial statements:<sup>6</sup> Mr. Paterson is a licensed certified public accountant in good standing with extensive experience in preparing, reviewing and auditing public company financial statements in accordance with US GAAP.

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

**Financial Statement Requirements:**

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable". Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

**10) Issuer Certification**

*Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, John O'Shea certify that:

1. I have reviewed this Disclosure Statement for CYIOS Corporation;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

4/ /2026 [Date]

---

<sup>6</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

/S/ John O'Shea [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

*Principal Financial Officer:*

I, John O'Shea certify that:

1. I have reviewed this Disclosure Statement for CYIOS Corporation;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

4/ /2026 [Date]

/S/ John O'Shea [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

**CYIOS Corporation**

**Consolidated Financial  
Statements Unaudited**

**For the Year Ended  
December 31, 2025**

# CONTENTS

	Page
CONSOLIDATED BALANCE SHEET.....	3
CONSOLIDATED STATEMENTS OF NET INCOME (LOSS).....	4
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY .....	5
CONSOLIDATED STATEMENTS OF CASH FLOWS.....	6
NOTES TO FINANCIAL STATEMENTS .....	7

**CYIOS CORPORATION**  
**CONSOLIDATED BALANCE SHEETS**  
(Unaudited)

	<b>As of December 31, 2025</b>	<b>As of December 31, 2024</b>
	<u>                    </u>	<u>                    </u>
<b>ASSETS</b>		
Cash	\$ 223	\$ 26,812
Accounts Receivable	495,219	273,955
Inventory	80,261	85,421
Related Party Receivable	352,180	268,350
Prepaid and Other Current Assets	40,864	65,505
Total Current Assets	<u>968,748</u>	<u>720,043</u>
Investments	-	-
Goodwill	-	-
<b>TOTAL ASSETS</b>	<u><u>968,748</u></u>	<u><u>720,043</u></u>
<b>LIABILITIES AND SHAREHOLDERS' DEFICIT</b>		
Accounts Payable and Accrued Expenses	\$ 480,913	\$ 812,925
Current Portion of Convertible Notes	1,981,190	1,701,555
Promissory Notes	52,700	545,419
Related Party Convertible Note	100,482	95,600
Related Party Payable	13,691	18,878
Total Current Liabilities	<u>2,628,977</u>	<u>3,174,377</u>
<b>SHAREHOLDERS' DEFICIT</b>		
Common Stock, \$.001 par value, 285,000,000 shares authorized, 337,593,993 and 280,363,756 shares issued and outstanding, respectively	337,594	280,364
Preferred Stock	48	56
Additional Paid-in Capital	30,242,663	29,874,766
Common Stock Issuable	97,942	226,142
Retained Deficit	<u>(32,338,476)</u>	<u>(32,835,662)</u>
Total Shareholder's Deficit	<u>(1,660,229)</u>	<u>(2,454,334)</u>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<u><u>\$ 968,747</u></u>	<u><u>\$ 720,043</u></u>

*The Accompanying Notes are an Integral Part of These Consolidated Financial Statements*

**CYIOS CORPORATION**  
**CONSOLIDATED STATEMENTS OF INCOME**  
(Unaudited)

	<b>For the Year Ended</b>	
	<b>December 31,</b>	
	<u><b>2025</b></u>	<u><b>2024</b></u>
<b>INCOME</b>		
Revenues	\$ 11,905,825	\$ 8,021,251
Less:		
Cost of Revenues	<u>10,320,162</u>	<u>7,487,071</u>
Gross Profit	1,585,663	534,180
<b>EXPENSES</b>		
Advertising and Promotion	39,723	120,202
Consulting	88,756	8,972
Legal and Professional Fees	72,353	38,539
Salaries & Wages	296,567	386,960
Commissions	624,313	240,068
General and Administrative	<u>425,495</u>	<u>67,099</u>
Total Expenses	1,547,208	861,840
Income (Loss) from Operations	38,456	(327,660)
<b>Other Income and Expense</b>		
Interest Expense	(318,298)	(399,215)
Other Income (Expense)	<u>777,028</u>	<u>(973,819)</u>
Total Other Income and Expense	458,730	(1,373,034)
<b>NET INCOME (LOSS)</b>	<u><u>\$ 497,186</u></u>	<u><u>\$ (1,700,694)</u></u>

*The Accompanying Notes are an Integral Part of These Consolidated Financial Statements*

**CYIOS CORPORATION**  
**CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY**  
(Unaudited)

	Common Stock		Preferred Stock		Additional Paid-In Capital	Common Stock Issuable	Retained Deficit	Total
	Shares	Amount	Shares	Amount				
Balance as of December 31, 2023	240,363,756	\$ 240,364	55,250	\$ 56	\$ 29,466,164	\$ 5,142	\$ (31,134,968)	\$ (1,423,242)
Conversion of accrued salary to stock	-	-	-	-	114,000	6,000	-	120,000
Stock issuable for services contract	-	-	-	-	(34,998)	140,000	-	105,002
Stock issued on debt conversion	40,000,000	40,000	-	-	329,600	-	-	369,600
Acquisition of Noir	-	-	-	-	-	75,000	-	75,000
Net loss for the period	-	-	-	-	-	-	(1,700,694)	(1,700,694)
Balance as of December 31, 2024	280,363,756	\$ 280,364	55,250	\$ 56	\$ 29,874,766	\$ 226,142	\$ (32,835,662)	\$ (2,454,334)
Common stock issuable for interest	-	-	-	-	-	17,800	-	17,800
Common stock converted to preferred	(7,000,000)	(7,000)	4,600	5	12,995	(6,000)	-	-
Stock issued on debt conversion	47,000,000	47,000	-	-	220,200	-	-	267,200
Stock issued on services contract	17,230,237	17,230	-	-	58,583	(75,813)	-	-
Discontinuation of subsidiary	-	-	-	-	82,607	-	-	82,607
Stock cancelled	-	-	(13,000)	(13)	(6,488)	(64,187)	-	(6,501)
Net income for the period	-	-	-	-	-	-	497,186	497,186
Balance as of December 31, 2025	337,593,993	\$ 337,594	46,850	\$ 48	\$ 30,242,663	\$ 97,942	\$ (32,338,476)	\$ (1,596,041)

*The Accompanying Notes are an Integral Part of These Consolidated Financial Statements*

**CYIOS CORPORATION**  
**CONSOLIDATED STATEMENT OF CASH FLOWS**  
(Unaudited)

	<b>For the Year Ended</b>	
	<b>December 30,</b>	
	<b>2025</b>	<b>2024</b>
<b>CASH FROM OPERATING ACTIVITIES</b>		
Net Income (Loss)	\$ 497,186	\$ (1,700,694)
Adjustments to reconciled net loss to net cash flow from operating activities:		
Loss on disposition of assets	-	925,000
Gain on cancellation of stock subscription	(65,000)	
Stock issued for debt and interest	285,000	345,600
Gain on debt forgiveness	(620,840)	
Change in operating accounts:		
Increase in accounts receivable	(221,264)	205,277
Decrease in inventory	5,160	(26,677)
Decrease in prepaid expenses	24,641	(31,678)
Increase in accounts payable and accrued expenses	(306,227)	163,476
Net Cash Used in Operating Activities	<u>(401,345)</u>	<u>(119,696)</u>
<b>CASH FROM INVESTING ACTIVITIES</b>	-	-
<b>CASH FROM FINANCING ACTIVITIES</b>		
Net proceeds from issuance of convertible notes	119,019	30,000
Proceeds from issuance of promissory notes	222,319	278,158
Net proceeds from related party borrowing	33,418	(168,306)
Net Cash Used in Financing Activities	<u>374,756</u>	<u>139,852</u>
Net change in cash and cash equivalents	(26,589)	20,156
Cash at beginning of period	26,812	6,657
Cash at the end of period	<u>\$ 223</u>	<u>\$ 26,813</u>
<b>SUPPLEMENTAL CASH FLOW INFORMATION</b>		
Cash Paid During the Period for:		
Taxes	\$ -	\$ -
Interest	\$ -	\$ -
Non-Cash Activities		
Common stock issued to retire debt and interest	\$ 285,000	\$ 377,600
Common stock issued on conversion of accrued salary		\$ 120,000

*The Accompanying Notes are an Integral Part of These Consolidated Financial Statements*

**CYIOS CORPORATION**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**For the Year Ended December 31, 2025**

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES

The Company's accounting policies conform to U.S. Generally Accepted Accounting Principles (USGAAP). The following policies are considered to be significant:

Business Organization

CYIOS Corporation (the Company) is incorporated in the State of Nevada. The Company was reorganized to engage in the business of developing and marketing specialty branded products in the Health and Wellness markets. The Company is currently headquartered in Florida. At this time, the Company is revenue producing and is selling products under its own private label and other branded products in the Health and Wellness market segment. On May 7, 2020, the Company acquired Choice Wellness Inc. In May, 2021, the Company acquired the assets of Helio Lending for a total of 15,000,000 shares of common stock and a commitment to issue an additional 15,000,000 common stock pending the realization of achieving certain revenue targets. The Company recorded a stock payable for \$675,000 to reflect this obligation which has been offset to Goodwill as the assets are intangible in nature. During the year ended December 31, 2023, the Company issued 30,000,000 shares of restricted common stock in stock to satisfy this obligation. During the year ended December 31, 2024, the Company determined that it was no longer feasible to continue the operations of Helio Lending and closed the associated operations thereof. As a result, the Company recorded a loss on disposition of assets of \$675,000 related to the recorded Goodwill. On August 10, 2024, the Company acquired 100% of the issued and outstanding ownership of Noir Medical Supply, LLC, a Florida company engaged in providing medical supplies, in exchange for six million (6,000,000) shares of CYIOS common stock. In September 2025, the company discontinued the operations of Choice Wellness, Inc. The only material balance on the books of Choice Wellness at the time was a working capital loan from a third party, which was assumed by CYIOS Corporation. All other intercompany assets and liabilities were offset against Additional Paid in Capital

The Company activities are subject to significant risks and uncertainties, including failing to secure the necessary funding to operationalize it plans.

Revenue Recognition / Source of Funding

The provisions of the FASB's ASC Topic 606, Revenue from Contracts with Customers, have been analyzed. It has been concluded that no changes are necessary to conform with the new standard. The program service fees are recognized at a point in time when service is provided, technical ownership, risks, and rewards are transferred. Funds received in advance of providing the services are recorded as deferred income until the services are provided. Contributions are recognized when pledged and recorded as net assets without donor restrictions or net assets with donor restrictions, depending on the existence and/or nature of any donor- imposed restrictions. Gifts of cash and other assets are reported with donor restricted support if they are received with donor stipulations that limit the use of the donated assets. When a restriction expires, that is, when a stipulated time restriction ends or a purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions. The company only bills customers once services or goods are provided and income is considered earned. The Company does not engage in progress billing.

### Principles of Consolidation

The consolidated financial statements include the Company's wholly owned subsidiary, Noir Medical Supply, LLC. All significant intercompany transactions are eliminated. There was no income or expense recorded between the companies during the periods presented. For Noir Medical Supply, only the results of operations from the date of acquisition (August 10, 2024) through period end date have been consolidated. The difference between the value of the shares issued to acquire Noir (\$75,000), and the net assets acquired (\$400,809), were recorded as a gain in Other Income as of the acquisition date.

### Use of Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with USGAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the reporting period. In these financial statements, assets, liabilities, and earnings involve reliance on management's estimates. Actual results could differ from those estimates.

## NOTE 2 - CONVERTIBLE NOTES PAYABLE

During January of 2016, the Company entered into a \$225,000 Convertible Loan Agreement with Azure Associates in exchange for non-assessable shares of the Company's Common Stock based upon a conversion price of \$.0003 per share with interest accruing at 0%. To comply with US GAAP, Company has applied an interest rate of 2.65% based upon the long-term federal funds rate when the convertible bond was issued. As of August 31, 2019, the Company agreed to restructure the convertible debt from a conversion price of \$.0003 per share to \$.001 per share. During the year ended December 31, 2021, the Company converted \$39,106, including interest. During the nine months ended September 30, 2022, the Company converted an additional \$10,000 of principle for 6,500,000 shares of common stock. During the quarter ended March 31, 2023, an additional \$3,500 was converted into 3,500,000 shares of common stock. During the quarter ended December 31, 2023, the Company issued 28,000,000 shares on the conversion of \$28,000 in principal, leaving a balance due as of December 31, 2023 is \$110,562. During the three months ended March 31, 2024, the Company issued an additional 16,000,000 shares of restricted common stock on the conversion of \$16,000 in note principal. 16,000,000 shares were issued on the conversion of \$16,000 in accrued interest on July 1, 2024 and 8,000,000 shares were issued on the conversion of \$8,000 in principle on October 10, 2024. During the quarter ended March 31, 2025, an additional 7,000,000 shares were issued on the conversion of \$7,000 in principle. During the quarter ended June 30, 2025, \$10,000 in principle was converted into 10,000,000 shares. During the quarter ended September 30, 2025, \$10,000 in principle was converted into 10,000,000 shares of common stock and during the quarter ended December 31, 2025, a further \$20,000 in principle was converted into 20,000,000 shares of common stock, leaving balance owed of \$23,562 as of December 31, 2025.

During the year ended December 31, 2021, the Company issued a \$255,000 a 6% per annum redeemable note. The note is due on February 10, 2022 and is convertible into common stock at a fixed price of .25 cents per share. As of December 31, 2025, the balance due was \$255,000.

During the year ended December 31, 2021, the Company issued a \$240,000 6% per annum convertible bond. The note is convertible into common stock at a fixed price of 12.5 cent per share. As of June 30, 2025, the balance due on the note was \$240,000. In May 2024, the Company was notified that the lender, Adar Bay, had been sanctioned by the Securities and Exchange Commission and that, as a result, all convertible features of this debt had been cancelled. As there were no derivative features associated with this loan, there is no impact of this change on the financial statements of the Company

During the year ended December 31, 2021, the Company issue a \$130,000 6% annum convertible bond due on May 4, 2022. The note is convertible into common stock at a fixed price of 12.5 cents per share. As of December 31, 2025, the balance due on the note was \$130,000.

During the year ended December 31, 2020, the Company entered into agreement with BB Winks LLC for a convertible grid promissory note for up to \$500,000. The initial terms required \$60,000 in initial funding prior to December 31, 2020. The note accrues interest annually at 8% per annum and any loans provided require payment within one year in cash or for common stock with a fixed price of \$.012 per share. At no time will the Company issue common shares that would result in the lender owning more than 9.99% of the common stock outstanding at the time of conversion. A total of \$500,000 has been drawn down against this note as of December 31, 2022. A second convertible grid promissory note for up to \$500,000 was entered into during the year ended December 31, 2022 under same terms but with a fixed conversion price of .025 per share. As of March 31, 2023, a total of \$245,000 had been drawn down under this note. The total balance owed to BB Winks under both notes as of June 30, 2025 was \$745,000. In September 2025, the Company and BB Winks reached an agreement where all notes plus accrued interest, with the exception of \$250,000, was forgiven. The debt forgiveness was recorded as Other Income in the accompanying financial statements. As of December 31, 2025 the balance owed was \$250,000.

On December 20, 2021, the Company issued a convertible note payable to Lance Quartieri in the amount of \$175,000 which is due 12 months from the date of issuance. The note is convertible into common shares of the Company stock at \$0.005 per share. In the quarter ended March 31, 2023, \$50,000 of this note was converted into 10,000,000 shares of common stock. In the quarter ending June 30, 2023, an additional \$67,500 was converted into 13,500,000 shares of common stock. As of December 31, 2025, the remaining principal balance due is \$57,500.

On November 20, 2023, the Company executed an 8% interest, convertible grid note payable with J-Ricks, LLC in the amount of \$500,000. The total advanced of \$384,899, including interest, was outstanding as of December 31, 2025. Under the terms of the note, the payee has the option to convert the balance of any outstanding principal and interest into common stock of the Company based on a fifty percent (50%) discount to the market price per share at the time of conversion or a fixed price of \$0.0015 per share.

In February 2025, the Company executed three convertible notes of \$25,000 each, totaling \$75,000, to three unrelated individuals. The notes are due February 9, 2026, earn interest at the rate of 10% per annum and are convertible into common stock at a share price equal to 65% of the average of the three lowest End of Day VWAP for the Common Stock during the 7 trading days preceding the Conversion Date, but in no event less than \$.00025 per share. As consideration for issuing the notes, each of the lenders will be issued 1,000,000 shares of common stock, the value of which were recorded as Common Stock Issuable in the accompanying financial statements based on the value of the stock on the date the monies were received.

In June 2025, the Company executed a note for \$47,500 with Pinnacle Consulting Services, Inc., of which \$7,500 was considered an issuance discount, netting the Company \$40,000. The note bears interest at twelve percent (12%) and is due November 30, 2025. Under the terms of the Note, the balance with any unpaid interest may be converted into common shares at the greater of 80% of the 10-day trailing VWAP or \$0.00025. If the stock trades below \$0.00025 for five consecutive days, the conversion floor drops to \$0.0001.

Combined, the Company has convertible notes outstanding, together with accrued interest, of \$1,981,190 as of December 31, 2025.

### NOTE 3 - RELATED PARTY PAYABLE

The Company entered into a loan agreement with OFBP Proprietary Limited (OFBP Pty Ltd) in the fourth quarter of 2018, for up to \$250,000 to pay for operational expenses. As of December 31, 2020, the balance under this loan was \$71,839. Interest accrued at 15% per annum on the outstanding balance. On January 2nd 2020, in exchange of this loan, the Company

issued a one-year Convertible Promissory Note to OFBP Pty, Ltd in the amount of \$71,839 for payments made by the investor on behalf of the Company to various third-party vendors, at the direction of the Company, during 2019. General terms of the Note are 6% annual interest and conversion terms of 25% discount into common shares. As of December 31, 2025, the balance of the Convertible Note Payable was \$100,482 including interest.

Beginning January 2, 2020, any new funds provided by OFBP will be a loan payable at 8% annual interest. During the year ended September 30, 2020, \$7,048 in payments made by the investor on behalf of the Company to various third-party vendors, at the direction of the Company. The Company closed out the agreement with OFBP during the 2<sup>nd</sup> quarter of 2020. As of December 31, 2025, the balance of the note payable, including interest, was \$13,691.

During the year ended December 31, 2024, the Company borrowed \$30,000 from the CEO of Noir, in the form of note convertible at 85% of the offering price of any future Reg A offering of CYIOS.

#### NOTE 4 - RELATED PARTY RECEIVABLE

During the year ending December 31, 2024, the Company loaned a total of \$180,000 to the Company's Chief Executive Officer in lieu of compensation. The balance, together with accrued interest at the rate of five percent (5%) is due before the end of 2025. In September 2025, this loan was forgiven as part of an agreement in which the CEO resigned from the Company. In return, the former CEO agreed to waive accrued compensation in the amount of \$254,089 and a personal loan to the Company of \$6,000. In total, the Company recorded a gain of \$86,589 on the separation which was recorded as Other Income in the accompanying financial statements.

#### NOTE 5 - COMMON STOCK ACTIVITY

The Company is authorized to issue 585,000,000 shares of common stock at \$.001 per share, of which 337,593,993 shares were issued and outstanding as of December 31, 2025.

During the three months ending March 31, 2024, the Company issued 16,000,000 shares on the conversion of \$16,000 in convertible notes payable that were originally issued to Azure Associates. The company recorded additional interest in the amount of \$158,400 resulting from the difference between the conversion price (\$0.001) and the closing bid price on the date of conversion.

There was no common stock activity during the three months ending June 30, 2024.

During the three months ending September 30, 2024, the Company issued 16,000,000 shares of common stock into J-Ricks on the conversion of \$16,000 in accrued interest related to a convertible note originally issued to Azure Associates in January 2016.

During the three months ending December 31, 2024, the company issued 8,000,000 shares to J-Ricks on the conversion of \$8,000 in convertible note principle.

During the three months ending March 31, 2025, the Company issued 7,000,000 shares to J-Ricks on the conversion of \$7,000 in convertible note principle. On January 2, 2025, the Company cancelled 3,500,000 shares previously issued to each of the Company's directors under their employment agreements in exchange for 2,500 shares of Preferred Stock, Series D.

During the three months ending June 30, 2025, the Company issued 10,000,000 shares to J-Ricks on the conversion of \$10,000 in convertible note principle.

During the three months ending September 30, 2025, the Company issued 17,230,237 shares of restricted stock to Intent Sciences on the legal settlement. The value of the shares on the date of settlement, \$75,813, was recorded offset to Common Stock Issuable with the balance \$65,000 recorded as Other Income. The company also issued 10,000,000 shares to J-Ricks on the conversion of \$10,000 in convertible debt previously acquired from Azure, Inc.

During the quarter ended December 31, 2025, the Company issued 20,000,000 shares of common stock to J-Rick on the conversion of \$20,000 in convertible debt previously acquired from Azure, Inc.

#### NOTE 5 - COMMON STOCK ISSUABLE

During the quarter ending March 31, 2024, the Company's officers each agreed to convert \$60,000 in accrued wages (\$120,000 total) into common stock of the Company at an agreed conversion rate of \$0.02 per share (6,000,000 shared total). These shares had not been issued as of December 31, 2024 and were recorded as Stock Subscription Payable. In March 2025, the Company agreed to issue 2,100 shares of Series D Preferred Stock in lieu of issuing to common shares.

During the quarter ending March 31, 2024, the Company entered into a 12-month consulting contract with Intent Sciences, LLC, pursuant to which the Company is obligated to issue common stock with a value of \$140,000, with an initial payment of 6,000,000 shares. In September 2025, the Company issued 17,230,237 shares in satisfaction of this obligation and cancelled the balance of the contract. As a result, the Company recorded a gain of \$64,187 as Other Income

On August 10, 2024, the Company consummated the acquisition of 100% of the controlling interest in Noir Medical Supplies, LLC in exchange for 6,000,000 shares of CYIOS common stock. The value of the stock on the date of acquisition, \$75,000, has been recorded as Stock Payable pending the physical issuance of the shares.

In February 2025, the Company agreed to issue a total of 3,000,000 shares of common stock as consideration for receiving notes payable totaling \$75,000, of which \$40,000 had been received as of March 31, 2025. The Company also received a \$15,000 working capital loan in February 2025 which was repaid in March 2025. As consideration for this loan, the Company agreed to issue 1,000,000 shares of common stock which had not been issued as of September 30, 2025. Accordingly, the Company recorded the value of 3,000,000 shares as of the date the funds were received (\$17,800) as Common Stock Issuable.

During the year ended December 31, 2025, the Company cancelled 13,000 shares of preferred stock previously issued to an officer of the Company and also agreed to cancel the pending issuance of common shares valued at \$64,187.

As of December 31, 2025, the Company has common stock issuable of \$97,942.

#### NOTE 6 - PREFERRED STOCK

As of September 30, 2025, the Company has authorized 15,000,000 preferred shares of which 4,940,000 remain undesignated.

##### Series A

The Company has authorized the issuance of up to 10,000,000 shares of \$.001 par value Series A preferred stock. The preferred stock carries a voting right of 20 votes per share and each share is convertible to 20 shares of common stock. During the year ending December 31, 2021, the Company had previously issued 10,000,000 shares of preferred stock which were returned as part of the settlement with a former CEO.

##### Series B

As of September 30, 2025, the Company is authorized the issue of up to 10,000 shares of \$.001 par value Series B preferred stock. Each holder of outstanding shares of Series B Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock equal to 0.1% of the total number of shares of Common Stock outstanding on the record date for such vote. In the quarter ending March 31, 2021, the Company had previously issued 10,000 shares of preferred stock to David Green for his service as CEO. Those shares were later converted to 2,348,103 common shares at \$.015 per share. Subsequently, the 10,000 shares of Series B we issued to Mr. John O'Shea at par value for services to the Company.

#### Series C

As of September 30, 2025, the Company is authorized to issue up to 15,000 shares of \$.001 par value Series C preferred stock. During the year ending December 31, 2020, the Company issued 15,000 shares of Series C to Mr. John O'Shea at par value for services to the Company. Each share of Series C Preferred Stock is convertible into a number of common shares equal to .001% of the number of common shares issued and outstanding on the date of conversion.

#### Series D

As of September 30, 2025 the Company is authorized to issue of up to 40,000 shares of \$.001 par value Series D preferred stock. As of September 30, 2020, the Company had issued 20,000 shares of preferred stock to acquire Choice Wellness, Inc. Additionally, 2,500 and 10,000 shares of Series D were issued at par value to Mr. John O'Shea and Mr. David Lewis, respectively, for services provided (2,500 to each for services provided to the Board of Directors and the other 7,500 to Mr. Lewis for service as the Chief Executive Officer (CEO). Each share of Series D Preferred Stock is convertible into a number of common shares equal to .001% of the number of common shares issued and outstanding on the date of conversion. During the year ending December 31, 2022, 2,250 shares of Series D stock were converted to 3,183,750 shares of common stock. During the three months ended March 31, 2025, the Company agreed to issue to John O'Shea and David Lewis, directors of the Company, a total of 4,600 shares of Series D in exchange for the cancellation of 7,000,000 shares of common stock and the conversion of 6,000,000 shares of common stock issuable from the prior cancellation of accrued salary. In September 2025, Mr. Lewis agreed to return and cancel all shares of Series D held by him as part of his resignation from the Company. This resulted in the cancellation of 13,000 shares.

#### NOTE 7 - PURCHASE OF SUBSIDIARIES

On August 10, 2024, the Company acquired 100% of the controlling interest in Noir Medical Supplies, LLC in exchange for 6,000,000 shares of CYIOS common stock, which was valued at \$75,000 on the date of closing. Net assets of Noir (assets less liabilities) on August 10, 2024 were \$400,809. The difference between the purchase price and the net asset value, \$325,809, has been recorded as a gain on acquisition during the period ending September 30, 2024. The balance sheets of Noir have been consolidated for all periods presented.

#### NOTE 8 - SUBSEQUENT EVENTS

Management noted that there have been no material transactions from the period ending December 31, 2025 through the date of this report apart from the following:

- In February 2026, , the Company agreed to issued 30,000,000 (thirty million) shares of restricted common stock to J-Ricks on the conversion of \$18,000 related to a Convertible Grid Promissory Note
- In April 2026, the Company agreed to issued 6,500,000 (six million five hundred thousand) shares of restricted common stock to John J. Van Wart in full satisfaction of the total amount of \$6,200.00 working capital loan advanced to the Company during 2025.